A retrospective, multicenter study of efficacy of either nivolumab-ipilimumab or pembrolizumab-axitinib combination as first-line treatment in metastatic renal cell carcinoma patients with poor performance status (PS≥2)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 21 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Axitinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
Indications Renal cell carcinoma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

26 Nov 2022 Results (n=70) published in the European Journal of Cancer
29 Mar 2022 New trial record
19 Feb 2022 Results (n=56) presented at the 2022 Genitourinary Cancers Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight